ASH 2023
Important data on transplant-eligible NDMM
Perseus, Iskia
ASH 2023
Important data on transplant-eligible NDMM
SWOG S0777/S1211, EMN20, Rest
ASH 2023
Update on transplant-ineligible NDMM
Perseus, IsKia, IFM 2018-04
ASH 2023
Quatruplet therapy - the new standard in induction &…
IsKia
ASH 2023
CD38 antibodies - good in 1st line but bad in 2nd line?
IsKia
ASH 2023
Isa-KRd - practice changing?
Perseus
ASH 2023
Practice changing - Daratumumab before und after…
IsKia
ASH 2023
CD38-antistoffer - bra i førstelinje men ikke i…
Perseus
ASH 2023
Daratumumab vor und nach Transplantation neuer Standard
Perseus, IsKia, IFM 2018-04
ASH 2023
Vierfachkombinationen - der neue Standard bei Induktion…
IsKia
ASH 2023
Isa-KRd - practice changing?
KarMMa-3
ASH 2023
The future of CAR T Cell treatment - I
CARTITUDE-2
ASH 2023
The future of CAR T Cell treatment - II
MonumenTAL-1
ASH 2023
Bispecific antibodies - update and outlook on treatment…
ASH 2023
New data on efficacy and safety of CAR T cells and…
ASH 2023
Early data on TriTac
CARTITUDE-2
ASH 2023
cilta-cel in early lines
ASH 2023
Response predictors in immunotherapy
ASH 2023
Single-cell analysis of CAR T cells
KarMMa-3
ASH 2023
Survival data from KarMMa-3
ASH 2023
Einzelzell-Analysen bei CAR-T-Zellen
CARTITUDE-2
ASH 2023
cilta-cel in frühen Linien
ASH 2023
CAR-T-Zellen und bispezifische Antikörper/TCEs: Neue…
KarMMa-3
ASH 2023
Overlevelsesdata fra KarMMa-3
CENTAURUS
ASH 2023
CENTAURUS: using single-drug Daratumumab in smoldering…
ASH 2023
First whole genome sequencing trial with long-term FUP…
Immuno-PRISM
ASH 2023
Are we preventing myeloma yet?
Istopmm
ASH 2023
Are we ready for screening?
CENTAURUS
ASH 2023
CENTAURUS: using single-drug Daratumumab in smoldering…
ASH 2023
First whole genome sequencing trial with long-term FUP…
ELARA, CO41942, LYSA
ASH 2023
Updates for immunotherapy of follicular lymphoma
ASH 2023
Cost-effectiveness analysis of Mosunetuzumab and CAR T…
TRANSCEND FL
ASH 2023
CAR T cells in follicular lymphoma (1st relapse)
ASH 2023
Chemo-free combination for 1st line follicular lymphoma
ASH 2023
Bispecific antibodies in follicular lymphoma (1st line)
Descart Registry Analysis from Lysa
ASH 2023
Real-world data of CAR T in relapsed follicular…
ELARA
ASH 2023
Long-term follow-up of ELARA study
ASH 2023
Una combinazione chemo-free per la prima linea del…
ELARA
ASH 2023
Follow-up a lungo termine dello studio ELARA
Descart Registry Analysis from Lysa
ASH 2023
Data "real world" delle CART nel linfoma follicolare…
TRANSCEND FL
ASH 2023
CAR-T-Zellen im follikulären Lymphom (erstes Rezidiv)
ASH 2023
Analisi costo-beneficio di mosunetuzumab vs CART nel…
ASH 2023
Bispezifische Antikörper im follikulären Lymphom (1st…
Ilyad
ASH 2023
No efficacy of vitamin D in rituximab therapy
Ilyad
ASH 2023
Keine Wirksamkeit von Vitamin D bei Rituximab-Therapie
ASH 2023
New data for MCL - part I
Lyma and Lyma-101 comparison, Sympatico
ASH 2023
New data for MCL - part II
SYMPATICO
ASH 2023
Ibrutinib plus Venetoclax in R/R MCL - a new treatment…
ASH 2023
Sequential use of R-bendamustine and ibrutinib?
ASH 2023
BOVEN: An effective MRD-guided strategy free of chemo…
Sympatico
ASH 2023
A new standard for R/R MCL?
ASH 2023
Adding Ara-C and lenalidomide to the standard RCHOP+RM…
ASH 2023
TP53-mutant MCL - a new standard in 1st line?
SYMPATICO
ASH 2023
The SYMPATICO study confirms the synergy between…
Lyma and Lyma-101 comparison
ASH 2023
Is obinutuzumab superior to rituximab in MCL?
ASH 2023
Venetoclax added to RBAC significantly improves PFS in…
ASH 2023
Sobering results for bendamustine and venotoclax in MCL…
ASH 2023
MCL mit TP53-Mutation: Neuer Standard in der Erstlinie?
ASH 2023
Añadir Ara-C y lenalidomida al estándar RCHOP+MR no…
Sympatico
ASH 2023
Ny standardbehandling för recidiv av MCL?
ASH 2023
Venetoclax mejora significativamente la PFS de RBAC en…
ASH 2023
BOVEN: Una estrategia sin quimio guiada por EMR,…
ASH 2023
Sekventiell eller samtidig behandling med R-bendamustin…
ASH 2023
Ernüchternde Ergebnisse für Bendamustin und Venotoclax…
SYMPATICO
ASH 2023
El estudio SYMPATICO confirma la sinergia entre…
Lyma and Lyma-101 comparison
ASH 2023
Vilken CD20-antikropp är att föredra vid MCL?
SYMPATICO
ASH 2023
Ibrutinib plus Venetoclax beim rezidivierenden MCL -…
GAIA/CLL13, FLAIR, ALPINE, ELEVATE-TN
ASH 2023
Highlights in chronic lymphocytic leukemia
BRUIN
ASH 2023
Pirtobrutinib in relapsed CLL
FLAIR
ASH 2023
Ibrutinib plus venetoclax as MRD-guided treatment
ASH 2023
Sonrotoclax plus zanubrutinib in 1st line CLL
ASH 2023
Bv-AVD in older patients
ASH 2023
Nivo-AVD bei älteren Patienten besser als Bv-AVD
ASH 2023
DLBCL - new treatment approaches and diagnostic…
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!